Skip to main content
Clinical Trials/NCT06029842
NCT06029842
Completed
Not Applicable

A Randomized Controlled Trial to Assess the Role of a Clinical Pharmacist in the Management of Type 2 Diabetic Patients for Optimum Treatment Outcomes in a Primary Medical Center in Jordan

University of Jordan1 site in 1 country103 target enrollmentOctober 17, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pharmacist-Patient Relations
Sponsor
University of Jordan
Enrollment
103
Locations
1
Primary Endpoint
HbA1c
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study aimed to assess the impact of the clinical pharmacist on enhancing type 2 diabetic patients outcomes in a primary health care center.

Detailed Description

About 103 patients with type 2 diabetes were randomized to control or intervention group, the control group received a standard care, while the intervention group received the collaborative care between the clinical pharmacist and physicians. Fasting blood glucose, HbA1c, Lipid profile, and blood pressure measured for both groups at baseline and after three months of follow-up. Treatment related problems (TRPs), quality of life, adherence, and patients knowledge about their medications were assessed. Cost avoidance and clinical significance of implemented clinical pharmacist interventions were assessed too.

Registry
clinicaltrials.gov
Start Date
October 17, 2022
End Date
April 24, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jyana Alelaimat

Master student at the University of Jordan

University of Jordan

Eligibility Criteria

Inclusion Criteria

  • type 2 diabetic patients who aged 18 years or more with a HbA1c reading 6.5 % or more at the time of diagnosis

Exclusion Criteria

  • pregnant patients
  • breastfeeding patients
  • patients with urgent or emergent cases
  • patients with cognitive impairment
  • if the patient is unable to provide informed written consent

Outcomes

Primary Outcomes

HbA1c

Time Frame: 3 months

Secondary Outcomes

  • Lipid profile(3 months)
  • Fasting blood glucose(each month for 3 months)
  • Patients knowledge about their medications(3 months)
  • Cost avoidance of implemented clinical pharmacist interventions(3 months)
  • Patients adherence to medications(3 months)
  • Quality of life(3 months)
  • Blood pressure(3 months)

Study Sites (1)

Loading locations...

Similar Trials